Boehringer buys Swiss biotech in its latest M&A deal, going the next-gen cancer vaccine route
Boehringer Ingelheim has snapped up a Swiss biotech startup and added their group as a new platform for the oncology pipeline.
The German biopharma company has bagged Geneva-based AMAL Therapeutics, paying out an unspecified upfront in a $358 million deal — cash, milestones and everything else, all in. Plus there’s 100 million euros on the line for commercial milestones.
Basic subscription required
Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.